Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCA | P06881 | 13/20 | 0.43 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.39 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | MYC | P01106 | 1/20 | 0.32 |
| ▸ | WDR5 | P61964 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13243792 | 0.95 | CALCA (0.44) | CALCALIPGAADATCYP2C9KCNH2 | |
| SCHEMBL2955395 | 0.94 | CALCA (0.38) | CALCALIPGAADATCYP2C9 | |
| SCHEMBL13243788 | 0.90 | CALCA (0.45) | CALCACYP2C9KCNH2 | |
| SCHEMBL2962478 | 0.90 | CALCA (0.39) | CALCALIPGAADATCYP2C9 | |
| SCHEMBL13243791 | 0.85 | CALCA (0.46) | CALCAAADATCYP2C9KCNH2 | |
| SCHEMBL2957301 | 0.84 | CALCA (0.40) | CALCACYP2C9KCNH2 | |
| SCHEMBL2967365 | 0.80 | CALCA (0.41) | CALCAAADATCYP2C9KCNH2 | |
| SCHEMBL13917566 | 0.79 | CALCA (0.44) | CALCALIPGCYP2C9 | |
| SCHEMBL13917556 | 0.79 | CALCA (0.46) | CALCALIPGCYP2C9KCNH2 | |
| SCHEMBL2957304 | 0.75 | CYP2C9 (0.39) | AADATCYP2C9KCNH2MYCWDR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7763630-B2 | pyrimidinone compounds such as N-(4-Fluorobenzyl)-5-hydroxy-1-methyl-6-oxo-2-(tetrahydrofuran-3-yl)-1,6-dihydropyrimidine-4-carboxamide, used for treating human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-27 | — | — | US | disclosed |
| US-7763630-B2 | pyrimidinone compounds such as N-(4-Fluorobenzyl)-5-hydroxy-1-methyl-6-oxo-2-(tetrahydrofuran-3-yl)-1,6-dihydropyrimidine-4-carboxamide, used for treating human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-27 | — | — | US | disclosed |
| WO-2008154246-A1 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-18 | — | — | WO | disclosed |
| US-20080306051-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-12-11 | — | — | US | disclosed |
| US-20080306051-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306051-A1 | HIV Integrase Inhibitors | TYMP, IMPDH1, UNG | CALCA 2954/4885LIPG 4508/4885AADAT 1332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.